# Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

> **NCT04139902** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Diwakar Davar** · enrollment: 48 (actual)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV

## Interventions

- **DRUG:** Dostarlimab (TSR-042) (singly)
- **DRUG:** Dostarlimab (TSR-042) and TSR-022 (combination)

## Key facts

- **NCT ID:** NCT04139902
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-12
- **Primary completion:** 2025-09-29
- **Final completion:** 2029-12-15
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04139902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04139902, "Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04139902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*